DIAN-TU Primary Prevention Trial for Dominantly Inherited Alzheimer’s Disease
Official title: DIAN-TU Primary Prevention Trial
Funded at Washington University · NIH-11579137 · Data updated 2026-11-12
This study tests a preventative treatment in people who carry genetic mutations for Alzheimer’s and are years away from symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 15, 2018 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $96,089 |
| NIH project number | 3R01AG059798-06S7 |
| Project ID | NIH-11579137 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals who carry a dominantly inherited Alzheimer’s disease mutation and are 11 to 25 years from estimated symptom onset, with minimal to no brain amyloid at trial entry.
✕Less likely to help
People without a dominantly inherited Alzheimer's mutation or those with advanced amyloid burden at entry may not benefit from this trial.
What this research studies
If you have a dominantly inherited Alzheimer's mutation, you may be eligible to join a multi-country, multi-site trial that tests whether early treatment can delay or prevent cognitive decline. The study uses a carefully designed, placebo-controlled approach to see if removing amyloid plaques before symptoms start can change the disease course. Participants are asymptomatic carriers who are far from the expected onset of symptoms, and the trial follows them through several stages to measure cognitive outcomes. The DIAN-TU platform supports this work, with oversight, standardized procedures, and international collaboration.
Why it matters
Potential benefit: If successful, this approach could delay or prevent dementia symptoms in people with a high genetic risk of Alzheimer’s disease.
How similar studies have gone: Prior studies targeting amyloid removal show cognitive benefits in some contexts, but this primary prevention approach is pioneering.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mcdade, Eric Martin — Washington University
- Study coordinator: Mcdade, Eric Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.